Yifeng Pharmacy Chain Co., Ltd.
SSE:603939.SS
25.02 (CNY) • At close June 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 24,062.155 | 22,588.227 | 19,886.396 | 15,326.305 | 13,144.502 | 10,276.175 | 6,912.577 | 4,807.249 | 3,733.619 | 2,845.516 | 2,230.226 | 1,804.299 | 1,539.478 | 1,224.108 |
| Cost of Revenue
| 14,408.311 | 14,030.232 | 12,025.564 | 9,142.818 | 8,152.071 | 6,267.593 | 4,166.082 | 2,882.583 | 2,254.464 | 1,729.16 | 1,343.23 | 1,106.831 | 966.144 | 784.103 |
| Gross Profit
| 9,653.844 | 8,557.995 | 7,860.832 | 6,183.487 | 4,992.432 | 4,008.581 | 2,746.495 | 1,924.666 | 1,479.155 | 1,116.356 | 886.995 | 697.469 | 573.334 | 440.004 |
| Gross Profit Ratio
| 0.401 | 0.379 | 0.395 | 0.403 | 0.38 | 0.39 | 0.397 | 0.4 | 0.396 | 0.392 | 0.398 | 0.387 | 0.372 | 0.359 |
| Reseach & Development Expenses
| 33.936 | 33.55 | 25.31 | 15.643 | 8.31 | 5.373 | 3.238 | 0 | 14.789 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 147.255 | 148.591 | 132.726 | 83.015 | 92.172 | 63.251 | 28.016 | 14.541 | 9.749 | 8.621 | 7.998 | 5.542 | 5.379 | 53.317 |
| Selling & Marketing Expenses
| 1,219.508 | 5,487.45 | 4,878.273 | 4,059.684 | 3,229.513 | 2,681.261 | 1,895.973 | 1,294.188 | 1,016.049 | 758.462 | 577.235 | 468.058 | 403.61 | 304.322 |
| SG&A
| 1,366.763 | 6,454.412 | 5,010.999 | 4,142.699 | 3,321.684 | 2,744.512 | 1,923.989 | 1,308.729 | 1,025.798 | 767.083 | 585.233 | 473.6 | 408.989 | 357.638 |
| Other Expenses
| 6,049.321 | 15.248 | 797.729 | 567.466 | 450.332 | 394.67 | 2.94 | 0.909 | 9.699 | 7.169 | 6.711 | 2.148 | 1.946 | 3.281 |
| Operating Expenses
| 7,450.02 | 6,503.21 | 5,834.038 | 4,725.807 | 3,780.327 | 3,144.555 | 2,200.686 | 1,521.091 | 1,195.806 | 896.875 | 699.482 | 563.563 | 480.612 | 366.148 |
| Operating Income
| 2,203.824 | 2,054.785 | 1,885.533 | 1,338.867 | 1,170.034 | 815.468 | 578.324 | 427.189 | 296.632 | 232.86 | 184.827 | 132.795 | 91.481 | 74.7 |
| Operating Income Ratio
| 0.092 | 0.091 | 0.095 | 0.087 | 0.089 | 0.079 | 0.084 | 0.089 | 0.079 | 0.082 | 0.083 | 0.074 | 0.059 | 0.061 |
| Total Other Income Expenses Net
| -21.377 | -17.191 | -8.046 | -0.961 | 30.43 | -1.172 | 2.86 | 0.909 | 9.69 | 6.742 | 6.488 | 2.324 | 0.448 | 3.093 |
| Income Before Tax
| 2,182.447 | 2,037.594 | 1,877.487 | 1,337.906 | 1,163.915 | 814.296 | 581.264 | 428.098 | 305.844 | 239.602 | 191.315 | 135.118 | 93.17 | 77.793 |
| Income Before Tax Ratio
| 0.091 | 0.09 | 0.094 | 0.087 | 0.089 | 0.079 | 0.084 | 0.089 | 0.082 | 0.084 | 0.086 | 0.075 | 0.061 | 0.064 |
| Income Tax Expense
| 529.665 | 456.663 | 450.292 | 347.157 | 297.06 | 205.412 | 139.695 | 110.628 | 77.925 | 61.365 | 48.913 | 34.737 | 23.634 | 20.913 |
| Net Income
| 1,528.577 | 1,411.985 | 1,261.841 | 887.884 | 743.523 | 543.75 | 416.414 | 313.504 | 223.891 | 175.936 | 140.561 | 99.188 | 68.604 | 55.879 |
| Net Income Ratio
| 0.064 | 0.063 | 0.063 | 0.058 | 0.057 | 0.053 | 0.06 | 0.065 | 0.06 | 0.062 | 0.063 | 0.055 | 0.045 | 0.046 |
| EPS
| 1.26 | 1.17 | 1.26 | 0.89 | 0.77 | 0.57 | 0.45 | 0.34 | 0.26 | 0.22 | 0.23 | 0.16 | 0.11 | 0.092 |
| EPS Diluted
| 1.24 | 1.17 | 1.26 | 0.89 | 0.77 | 0.57 | 0.45 | 0.34 | 0.26 | 0.22 | 0.23 | 0.16 | 0.11 | 0.092 |
| EBITDA
| 4,286.431 | 3,846.941 | 3,641.999 | 2,698.378 | 2,147.846 | 954.812 | 661.282 | 493.157 | 402.602 | 246.632 | 206.323 | 154.477 | 108.153 | 74.594 |
| EBITDA Ratio
| 0.178 | 0.17 | 0.183 | 0.176 | 0.163 | 0.093 | 0.096 | 0.103 | 0.108 | 0.087 | 0.093 | 0.086 | 0.07 | 0.061 |